293 related articles for article (PubMed ID: 26918343)
1. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
4. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
5. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Cho YH; Yazici H; Wu HC; Terry MB; Gonzalez K; Qu M; Dalay N; Santella RM
Anticancer Res; 2010 Jul; 30(7):2489-96. PubMed ID: 20682973
[TBL] [Abstract][Full Text] [Related]
8. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Sturgeon SR; Balasubramanian R; Schairer C; Muss HB; Ziegler RG; Arcaro KF
Epigenetics; 2012 Nov; 7(11):1258-67. PubMed ID: 22986510
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry.
Yazici H; Terry MB; Cho YH; Senie RT; Liao Y; Andrulis I; Santella RM
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2723-5. PubMed ID: 19755643
[TBL] [Abstract][Full Text] [Related]
11. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
12. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.
Kloten V; Becker B; Winner K; Schrauder MG; Fasching PA; Anzeneder T; Veeck J; Hartmann A; Knüchel R; Dahl E
Breast Cancer Res; 2013 Jan; 15(1):R4. PubMed ID: 23320751
[TBL] [Abstract][Full Text] [Related]
14. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
16. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
17. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.
Zhang YJ; Wu HC; Shen J; Ahsan H; Tsai WY; Yang HI; Wang LY; Chen SY; Chen CJ; Santella RM
Clin Cancer Res; 2007 Apr; 13(8):2378-84. PubMed ID: 17438096
[TBL] [Abstract][Full Text] [Related]
18. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
[TBL] [Abstract][Full Text] [Related]
19. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation Profiles and Their Diagnostic Utility in BC.
Shan M; Zhang L; Liu Y; Gao C; Kang W; Yang W; He Y; Zhang G
Dis Markers; 2019; 2019():6328503. PubMed ID: 31198475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]